Regulatory framework for polymer-based nanotherapeutics in clinical translation

Area of Science:

• * Nanomedicine and Pharmaceutical Sciences
• * Regulatory Science and Drug Development

Background:

• * Polymer-based nanotherapeutics (PNs) offer advanced drug delivery with controlled release and targeting.
• * Existing regulatory frameworks inadequately address the unique physicochemical and nanoscale properties of PNs.
• * Current regulations lead to inconsistent, case-by-case evaluations, hindering widespread clinical adoption.

Purpose of the Study:

• * To review critical quality attributes and analytical challenges for PNs.
• * To identify gaps in standardization that impede the clinical translation of PNs.
• * To advocate for a harmonized regulatory approach for nanotherapeutics.

Main Methods:

• * Comprehensive literature review of PNs, their characterization, and regulatory landscapes.
• * Analysis of current regulatory guidelines and their applicability to nanomedicines.
• * Examination of challenges in manufacturing scalability and in vivo performance prediction.

Main Results:

• * Significant gaps exist in characterizing PN physicochemical properties and ensuring manufacturing scalability.
• * The predictability of in vivo performance for PNs remains limited under current assessment models.
• * A mismatch is evident between the nanoscale nature of PNs and conventional regulatory expectations.

Conclusions:

• * Existing regulatory frameworks are insufficient for polymer-based nanotherapeutics.
• * A unified, science-based regulatory strategy is essential for PNs.
• * Harmonized standards will ensure the safety, efficacy, and global accessibility of nanotherapeutics.